Experimental Immunotherapy of Breast Cancer Using Alpha Interferon Conjugated to Monoclonal Antibody Mc5

  • Luciano Ozzello
  • Carolyn M. De Rosa
  • David V. HabifSr.
  • Edward W. Blank
  • Roberto L. Ceriani
  • Kari Cantell
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 353)

Abstract

In recent years, rapidly advancing knowledge on biological response modifiers and the advent of monoclonal antibodies (MoAbs) have provided renewed incentives for immunotherapy of malignant neoplastic diseases. Indeed, important progress has been made in the management of several solid tumors and leukemias through a variety of immunological manipulations, 1,2 while other tumors, including carcinomas of the breast, have thus far been regarded as poor candidates for immunotherapy. Nevertheless, some encouraging local results have been obtained in breast cancer recurrences and metastases treated with intralesional (i.l.) injections of interferons (IFNs). 3-5 A recent study has shown that natural interferon-α combined to natural interferon-γ (nIFN-α/nIFN-γ) delivered i.l. to recurrences and metastases of carcinomas of the breast can effectively eradicate the tumor cells apparently through direct antineoplastic effects and enhancement of cell-mediated immunological responses. 5

Keywords

Formalin Albumin Leukemia Glycine Oncol 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    D. Goldstein, and J. Laszlo, Interferon therapy in cancer: from imaginon to interferon, Cancer Res. 46: 4315 (1986).PubMedGoogle Scholar
  2. 2.
    S.A. Rosenberg, The immunotherapy and gene therapy of cancer, J. Clin. Oncol. 10: 180 (1992).PubMedGoogle Scholar
  3. 3.
    G.P. Murphy, Current report on the interferon program at Rosewell Park Memorial Institute, J. Surg. Oncol. 17: 99 (1981).PubMedCrossRefGoogle Scholar
  4. 4.
    R. Rosso, M.T. Nobile, M.R. Sertoli, A. Giannitelli, P.L. Santi, R. Volpe, and G. Nicolo, Antitumoral activity of human fibroblast interferon administered intranodularly, Oncology 42: 86 (1985).PubMedCrossRefGoogle Scholar
  5. 5.
    L. Ozzello, D.V. Habif, C.M. De Rosa, and K. Cantell. Cellular events accompanying regression of skin recurrences of breast carcinomas treated with intralesional injections of natural interferons α and γ, Cancer Res, 52: 4571 (1992).PubMedGoogle Scholar
  6. 6.
    L. Ozzello, D.V. Habif, CM. De Rosa, and K. Cantell, Treatment of human breast cancer xenografts using natural interferons-α and-γ injected singly or in combination, J.interferon Res. 8: 679 (1988).PubMedCrossRefGoogle Scholar
  7. 7.
    F.R. Balkwill, E.M. Moodie, V. Freedman, and K.H. Fantes, Human interferon inhibits the growth of established human breast tumors in the nude mouse, int. J.Cancer 30: 231 (1982).PubMedCrossRefGoogle Scholar
  8. 8.
    R.L. Ceriani, J.A. Peterson, J.Y. Lee, R. Moncada, and E.W. Blank, Characterization of cell surface antigens of human mammary epithelial cells with monoclonal antibodies prepared against human milk fat globule, Somat. Cell Genet. 9: 415 (1983).PubMedCrossRefGoogle Scholar
  9. 9.
    R.L. Ceriani, E.W. Blank, and J.A. Peterson, Experimental immunotherapy of human breast carcinomas implanted in nude mice with a mixture of monoclonal antibodies against human milk fat globule components, Cancer Res. 47: 532 (1987).PubMedGoogle Scholar
  10. 10.
    R.L. Ceriani, and E. W. Blank, Experimental therapy of human breast tumors with 131I-labeled monoclonal antibodies prepared against the human milk fat globule, Cancer Res. 48: 4664 (1988).PubMedGoogle Scholar
  11. 11.
    L. Ozzello, CM. De Rosa, E.W. Blank, K. Cantell, D.V. Habif, and R.L. Ceriani, Potentiation of anti-tumor efficacy resulting from the combined administration of interferon α and of an anti-breast epithelial monoclonal anibody in the treatment of breast cancer xenografts, in: “Breast Cancer Immunodiagnosis and Immunotherapy,” R.L. Ceriani, ed., Plenum Press, New York (1989).Google Scholar
  12. 12.
    K. Cantell, S. Hirvonen, H-L. Kauppinen, and G. Myllyla, Production of interferon in human leukocytes from normal donors with the use of Sendai virus. Methods Enzymol. 78: 29 (1981).PubMedCrossRefGoogle Scholar
  13. 13.
    H-L. Kauppinen, S. Hirvonen, and K. Cantell, Effect of purification procedures on the composition of human leukocyte interferon preparations, Methods Enzymol. 119: 27 (1986).PubMedCrossRefGoogle Scholar
  14. 14.
    J.L. Dickerson, J.J. Cornuc, and D.C. Rees, Complex formation between flavodoxin and cytochrome C, J. Biol. Chem. 260: 5175 (1985).PubMedGoogle Scholar
  15. 15.
    L. Ozzello, and M. Sordat, Behavior of tumors produced by transplantation of human mammary cell lines in athymic nude mice, Eur. J. Cancer 16: 553 (1980).PubMedCrossRefGoogle Scholar
  16. 16.
    K. Inoue, S. Fujimoto, and M. Ogawa, Antitumor efficacy of seventeen anticancer drugs in human breast cancer xenograft (MX-1) transplanted in nude mice, Cancer Chemother. Pharmacol. 10: 182 (1983).PubMedCrossRefGoogle Scholar
  17. 17.
    K. Cantell, S. Hirvonen, and H-L. Kauppinen, Production and partial purification of human immune interferon. Methods Enzymol. 119: 54 (1986).PubMedCrossRefGoogle Scholar
  18. 18.
    H-L. Kauppinen, B. Bang, J. Eronen, R. Majuri, G. Myllyla, H. Tolo, S. Hirvonen, and K. Cantell, Preparation of natural human gamma interferon for clinical use. in: “The Biology of the Interferon System”, W.E. Stewart and H. Schellekens eds., Elsevier, Amsterdam (1986).Google Scholar
  19. 19.
    R. Tran, P. Horan Hand, J.W. Greiner, S. Pestka, and J. Schlom, Enhancement of surface antigen expression on human breast carcinoma cells by recombinant human interferons, J. Interferon Res. 8: 75 (1988).PubMedCrossRefGoogle Scholar
  20. 20.
    J.A. Leon, R. Mesa-Tejada, CM. Gutieriez, A. Estabrook, J.W. Greiner, J. Schlom, and P.B. Fisher, Increased surface expression and shedding of tumor associated antigens by human breast carcinoma cells treated with recombinant human interferons or phorbol ester tumor promotors, Anticancer Res. 9: 1639 (1989).PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1994

Authors and Affiliations

  • Luciano Ozzello
    • 1
  • Carolyn M. De Rosa
    • 1
  • David V. HabifSr.
    • 1
  • Edward W. Blank
    • 2
  • Roberto L. Ceriani
    • 2
  • Kari Cantell
    • 3
  1. 1.College of Physicians and SurgeonsColumbia UniversityNew YorkUSA
  2. 2.Cancer Research Fund of Contra CostaWalnut CreekUSA
  3. 3.National Public Health InstituteHelsinkiFinland

Personalised recommendations